Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an update.
MicroPort CardioFlow Medtech Corporation has called an extraordinary general meeting (EGM) for 11 February 2026 in Shanghai, where shareholders will vote on a proposed share consolidation at a ratio of five existing shares into one consolidated share. The move, which is subject to Hong Kong Stock Exchange approval, would adjust the company’s share capital structure by increasing the par value per share while keeping the overall authorised capital unchanged, with fractional shares to be aggregated and potentially sold for the company’s benefit, signaling a bid to streamline its share base and potentially enhance trading efficiency and market perception.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a Hong Kong-listed medical technology company focused on cardiovascular interventions. It develops and manufactures cardiac-related medical devices and solutions, serving patients and healthcare providers primarily in China and other global markets, with an emphasis on innovative therapies for structural heart and vascular diseases.
Average Trading Volume: 4,813,460
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.56B
For detailed information about 2160 stock, go to TipRanks’ Stock Analysis page.